IGF1 and cancer: Consequently, numerous therapeutic strategies have been developed to inhibit or prevent the activation of the IGF signaling pathway in cancer cells, primarily through IGF-1R blocking antibodies and tyrosine kinase inhibitors that impede the tyrosine kinase domains of IGF-1R and IR [79,80].